Prostate Cancer Support Group - Richmond, Va Meeting Dates - 3rd Thurs. each month - Time 7:00 PM - No July Meeting - The Dec. date will vary - Call for details - Peter C. Moon Phd. at 804-387-2151 between 7 - 11:00 PM - Location - Ridge Baptist Church, 1515 Eastridge Road Richmond, VA 23229 Rva Prostate Cancer Support Group www.rvaprostatecancersupport.org RVA ADT (Androgen Deprivation Therapy) Page In good faith, this website was created to furnish you with helpful information. Nevertheless, no one who contributes or posts information to this website makes any guarantee regarding the information provided. Any decisions that you make regarding your health should be made in consultation with a qualified healthcare provider. Affiliated with Us-TOO International Prostate Cancer Education & Support Network

*******************************************************************************************************
ADT (Androgen Deprivation Therapy)

Prostate Cancer
***********************************************************************************************
Us Too Warriors,
All cardiac Deaths on ADT (Lupron) was 4.78X higher than men with PCa of age 70 to 79 website Link Below"

Us Too Warriors,
This is another reason I have been avoiding Lupton etc for 28 years, If you are on Lupron you need to have a cardiologist do everything to protect your heart. Remember your heart is a muscle and Lupron among its many faults is it causes muscle loss and also the weight gain that it induces is hard on the heart. Exercise is harder to do from fatigue but it is one of the few actions that helps

Best
Peter

FRIDAY, July 29, 2022 (HealthDay News) -- For patients with prostate cancer, use of androgen-deprivation therapy (ADT) is associated with an increased risk for cardiovascular disease (CVD) death, according to a study published online July 26 in The Aging Male.

Justinas Jonusas, from the National Cancer Institute in Vilnius, Lithuania, and colleagues examined the risk for CVD mortality in a retrospective cohort study of patients aged 40 to 79 years diagnosed with prostate cancer between Jan. 1, 2012, and Dec. 31, 2016. The final cohort included 13,343 prostate cancer patients who exclusively used gonadotropin-releasing hormone agonists.

To read more Go to the Website - Click on the Link Below:

Link 1 : "Website"
or Go To
https://www.practiceupdate.com/news/38817/3/3?elsca1=emc_enews_top-10&elsca2=email&elsca3=practiceupdate_uro&elsca4=urology&elsca5=newsletter&rid=NTU2MjE4MTA4NzMS1&lid=20845145

*******************************************************
Us Too Warriors,

This is better for the heart than Lupron - if on ADT.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Conclusions:
In this trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events. (Funded by Myovant Sciences; HERO ClinicalTrials.gov number, NCT03085095.).
Best Peter

To Read More:

Click on the Link:

Link: "Relugolix"
or Go To
https://pubmed.ncbi.nlm.nih.gov/32469183/

*******************************************************************************************************
Cognitive Function and Hormone Therapy in Advanced Prostate Cancer - Conversation with Alicia Morgans and Charles Ryan
Dr. Charles Ryan sits down with Dr. Alicia Morgans to discuss the study she's currently leading on Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer. This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. Specifically, enzalutamide seems to impact the cognitive vigor of some patients, however Dr. Morgans notes that there is a spectrum of cognitive change that can range from mild impairment to dementia. Currently, there is no real standardized process to identify cognitive function levels, so this is a work in progress that continues to evolve. The goal is to identify those people who are at highest risk and recommend interventions.
Click on Our Link to see the Presentation
Video
or Go To
https://www.urotoday.com/video-lectures/advanced-prostate-cancer/video/mediaitem/865-embedded-media2017-11-13-21-07-56.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
COGCaP: An Investigation into the Cognitive Side Effects of Androgen Receptor Targeted Therapies
Written By: Alicia Morgans
Whether androgen deprivation therapy (ADT) affects the cognitive function of men with prostate cancer remains controversial. While some studies have demonstrated that ADT impairs cognitive function, other studies have not found any such association.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/94421-cogcap-an-investigation-into-the-cognitive-side-effects-of-androgen-receptor-targeted-therapies.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review
Androgen deprivation therapy (ADT) is a common treatment for metastatic hormone-sensitive prostate cancer. Over 500,000 men are current on an ADT regimen. However, ADT does have some notable side-effects.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/conference-highlights/asco-gu-2017/asco-gu-2017-prostate-cancer/94136-asco-gu-2017-adverse-effects-of-adt-on-cognitive-function-and-dementia-for-men-with-prostate-cancer-a-meta-analysis-and-systematic-review-poster-session-highlights.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
From the Desk of the Associate Editor: Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
Androgen deprivation therapy causes a host of well-recognized side effects. Recent epidemiological and clinical evidence suggests that ADT may also be associated with dementia and cognitive impairment.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/journal/prostate-cancer-and-prostatic-diseases/from-the-editor/96758-from-the-desk-of-the-associate-editor-androgen-deprivation-therapy-for-prostate-cancer-and-dementia-risk-a-systematic-review-and-meta-analysis.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
A Randomized Phase II Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer
Ascorbic acid (vitamin C) is being used by complementary medicine practitioners to treat cancer, infections, and other conditions. Annual administration of more than 355,000 doses of intravenous (I.V.) ascorbic acid for more than 10,000 patients has been documented. Phase I and II clinical trials in 2012, 2013, and 2014 demonstrated safety and anti-tumor activity for high dose I.V. ascorbic acid.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/recent-abstracts/urologic-oncology/mcrpc-treatment/95195-a-randomized-phase-ii-trial-of-ascorbic-acid-in-combination-with-docetaxel-in-men-with-metastatic-prostate-cancer.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
ASCO 2017: Physical and Cognitive Effects of Systemic Therapy in Older Men with Prostate Cancer
Dr. Alicia Morgans from Vanderbilt University concluded the “Disparities in Screening and Treatment of Prostate Cancer for the Older Patient” session at the 2017 ASCO meeting with an excellent talk regarding the physical and cognitive effects of systemic therapy in older men with prostate cancer.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96342-asco-2017-physical-and-cognitive-effects-of-systemic-therapy-in-older-men-with-prostate-cancer.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
Clinical Trials:
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/clinical-trials/prostate-cancer/100188-cognitive-effects-of-androgen-receptor-ar-directed-therapies-for-advanced-prostate-cancer.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older
The purpose of this study is to find out if therapy with hormones (such as Lupron, Casodex, Zolodex or Degarelix) change a person's thinking abilities.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/clinical-trials/prostate-cancer/93575-the-impact-of-androgen-ablation-therapy-on-cognitive-functioning-and-functional-status-in-men-with-prostate-cancer-age-65-and-older.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.
Hormone therapy is a common cancer treatment that may be associated with numerous side and late effects, and in recent years, has been linked to changes in cognition.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/92867-cognitive-impairment-following-hormone-therapy-current-opinion-of-research-in-breast-and-prostate-cancer-patients.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************
Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
New generation hormone-therapies targeting the androgen signaling pathway are nowadays proposed to elderly patients with metastatic castration-resistant prostate cancer.
Click on Our Link to read the Presentation
Read
or Go To
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/97973-impact-of-new-generation-hormone-therapy-on-cognitive-function-in-elderly-patients-treated-for-a-metastatic-prostate-cancer-cog-pro-trial-protocol.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer
*******************************************************************************************************
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis

BACKGROUND: Androgen deprivation therapy (ADT) to treat prostate cancer may be associated with an increased risk of dementia, but existing studies have shown conflicting results. Here we synthesize the literature on the association of ADT for the treatment of prostate cancer with dementia risk.
Click on Our Link to read more
Meta-Analysis
or go to:
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/94421-cogcap-an-investigation-into-the-cognitive-side-effects-of-androgen-receptor-targeted-therapies.html?utm_source=newsletter_5044&utm_medium=email&utm_campaign=cognitive-functions-in-advanced-prostate-cancer

*******************************************************************************************************
(Us Too Warriors, Vitamin D3 and K2 can help increase BMD. Peter)
Abstract - Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.
INTRODUCTION:
Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT.

Click on Our Link to read more
BMD
or go to:
https://www.ncbi.nlm.nih.gov/pubmed/29051709
*******************************************************************************************************
Videos:

Us Too warriors - The following website (I hope) will help you negotiate your ADT therapy better

On This Site You will find:

These are downloadable slide decks from the symposium “Navigating the Adverse Effects of ADT: Improving Patient Outcomes” presented in conjunction with the AUA Annual Meeting on May 14, 2017.

This program emphasizes the importance of considering adverse effects of ADT treatment in patients with prostate cancer including hot flashes, bone adverse effects, ADT mechanisms of action, cardiovascular health, and current challenges.

Click on Our Link to view the Videos
Videos
or go to:
http://www.grandroundsinurology.com/navigating-adverse-effects-adt-slidedeck/
*******************************************************************************************************
Article:

Androgen Receptor Inhibitor - induced "BRCAness" and PARP inhibition
are synthetically lethal for castration-resistant prostate cancer.
On This Site You will find:

Cancers with loss-of-function mutations in BRCA1 or BRCA2 are deficient in the DNA damage repair pathway
called homologous recombination (HR), rendering these cancers exquisitely vulnerable to poly(ADP-ribose)
polymerase (PARP) inhibitors.

Click on Our Link to read more
Androgen Receptor Inhibitor
or go to:
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/95995-androgen-receptor-inhibitor-induced-brcaness-and-parp-inhibition-are-synthetically-lethal-for-castration-resistant-prostate-cancer.html
*******************************************************************************************************
A Review of Recent Data on Disease-related Outcomes Comparing Agonists and Antagonists for ADT
Thomas E. Keane, MD
Professor and Chairman of the Department of Urology
Medical University of South Carolina, Charleston, SC USA

Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane
has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants
from the National Institutes of Health as well as industry-funded.

To View This Video Presentation - Click on Our Link
ADT
or go to:
https://www.urotoday.com/video-lectures/advanced-prostate-cancer/video/mediaitem/498-a-review-of-recent-data-on-disease-related-outcomes-comparing-agonist-and-antagonists-for-adt.html
************************************************************************************************
Article:

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade.
On This Site You will find:

Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause
of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is
limited, making the identification of novel therapies for mCRPC critical.

Click on Our Link to read more
Lipid Catabolism
or go to:
https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/95534-lipid-catabolism-inhibition-sensitizes-prostate-cancer-cells-to-antiandrogen-blockade.html
*******************************************************************************************************
URO Today
Your Urology News and Education Resource.

Here you will find Articles, Videos Lectures, Clinical Trials and more. All are Choice topics on Immunotherapy.
Look Around the site & find the Topic that suits your needs by clicking on their links.

UroToday always offers free, open access to all site content - Enter your email address to sign in and
they will send you an Email link to sign in with.

To Read The Articles - Click on Our Link

URO Today

or go to:

https://www.urotoday.com/

**********************************************************************************